Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

CareDx Leads Transplant Innovation with AiKidney, an AI Clinical Decision Support Tool for Predicting Allograft Rejection Risk

Data from AiKidney Helps Clinicians Gain New Insights into Patient’s Risk of Allograft Rejection

CareDx to Host Investor Event to Share More Information About AiKidney, Clinical Pipeline and Using Augmented Information in Transplantation

CareDx, Inc.  – The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – announced that it plans to expand its growing multimodality portfolio with AiKidney, a new allograft risk assessment clinical decision support tool, in development, that includes AlloSure and other transplant metrics.

Latest Aithority Insights: Top Skills Needed to Become an AI Engineer

“AiKidney supports this assessment by providing information about a patient’s risk of allograft rejection and expected long-term graft survival. I am excited with innovations such as this one that have the potential to help prolong kidney allograft survival which remains suboptimal at the 10-year mark. “ ”

This follows CareDx’s recently announced plans to add an artificial intelligence (AI) prognostic for cardiac allograft vasculopathy (CAV). Presentations covering these developments will occur during the 2022 Transplant Congress on June 4-8 in Boston, Massachusetts.1

Related Posts
1 of 29,097

AiKidney delivers information about a patient’s current risk of rejection and a prognosis of allograft survival at three, five, and seven years. AiKidney can be used for informing clinical management decisions and to help clinicians predict the long-term impact of treatments. As transplant patient care becomes more complex, with an increasing focus on optimizing immunosuppression and long-term care, AlloSure is the only donor-derived cell-free DNA (dd-cfDNA) solution that features this additive AI-enabled risk assessment algorithm.

Data Privacy and SecurityChicago Public Schools Suffers Major Data Breach Affecting 100K Accounts

“CareDx is driving the next wave of transplant innovation with multimodality that amplifies the power of AlloSure by incorporating artificial intelligence.2 AiKidney has the potential to set a new standard of care through precision medicine by generating new insights to support earlier interventions or to modulate immunosuppression when assessing the risk of rejection by physicians,” said Reg Seeto, CEO and President of CareDx. “This approach aligns very much with our mission of improving long-term outcomes through innovative solutions.”

“We’re proud to work with CareDx to apply innovative digital health solutions to drive earlier data-driven interventions with molecular precision,” said Dr. Alex Loupy, Founder of OrganX. “This ongoing partnership is yielding positive results and it is exciting to see AiKidney coming to fruition in the clinic.”

“Studies have shown the effectiveness of CareDx’s multimodality solutions for routine kidney transplant surveillance and for identifying immune-quiescence,”3-5 said Miklos Z. Molnar, MD, PhD, Professor of Medicine and Medical Director of Kidney and Pancreas Transplantation at University of Utah. “AiKidney supports this assessment by providing information about a patient’s risk of allograft rejection and expected long-term graft survival. I am excited with innovations such as this one that have the potential to help prolong kidney allograft survival which remains suboptimal at the 10-year mark. “

Top Machine Learning InsightsLivePerson Collaborates with UCSC to Build the Future of Natural…

[To share your insights with us, please write to sghosh@martechseries.com]

Comments are closed.